Welcome to our dedicated page for Ani Pharmaceutic news (Ticker: ANIP), a resource for investors and traders seeking the latest updates and insights on Ani Pharmaceutic stock.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company with an active flow of corporate, clinical, and financial news. The company develops, manufactures, and commercializes therapeutics through its Rare Disease, Generics, and Brands businesses, and its communications frequently highlight progress in these areas. Investors following ANIP news can track how the Rare Disease segment, including products such as ILUVIEN and Purified Cortrophin Gel, contributes to the company’s growth alongside its generics and branded drug portfolios.
News updates for ANI often cover financial results and guidance, including quarterly earnings releases, adjusted non-GAAP metrics, and full-year outlooks. Press releases and related Form 8-K filings provide detail on net revenues by segment, the performance of key products, and management’s commentary on business trends. These disclosures also outline how Rare Disease revenues, particularly from Cortrophin Gel and ILUVIEN, compare with contributions from Generics and Brands.
ANIP news also includes clinical and medical developments, such as results from the NEW DAY clinical trial of ILUVIEN in diabetic macular edema and their presentation at major ophthalmology and retina meetings. The company reports on initiatives like the FutureVision Advisory Council, a group of retina and uveitis specialists formed to help guide its ophthalmology and retina franchise. Updates on Phase 4 trials, label transitions, and adoption trends for ILUVIEN and related products are also featured.
In addition, ANI regularly announces corporate and governance updates, including board transitions and leadership roles, as well as participation in healthcare and investor conferences hosted by organizations such as J.P. Morgan, Piper Sandler, Jefferies, H.C. Wainwright, and Morgan Stanley. These events often involve presentations or fireside chats where management discusses strategy, the transformation toward a rare disease–focused profile, and capital allocation priorities.
By monitoring ANIP news, readers can follow developments across rare disease therapeutics, generics, branded products, clinical research, and capital markets activity, all of which shape the company’s trajectory.
ANI Pharmaceuticals (Nasdaq: ANIP) reported preliminary, unaudited full year 2025 results and provided full year 2026 guidance on Jan 12, 2026. ANI expects 2025 total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS to be within or above prior guidance ranges of $854M–$873M, $221M–$228M, and $7.37–$7.64, respectively. Cortrophin Gel net revenues were approximately $347.8M in 2025 (up 76% YoY) and $111.4M in Q4 2025 (up 88% YoY). 2026 guidance: $1,055M–$1,115M total net revenues; Cortrophin Gel $540M–$575M; adjusted non-GAAP EBITDA $275M–$290M; adjusted non-GAAP diluted EPS $8.83–$9.34. ANI expects Rare Disease to be ~60% of 2026 revenue, plans a ~90-person Rare Disease expansion, and will present at the J.P. Morgan Healthcare Conference on Jan 13, 2026.
ANI Pharmaceuticals (Nasdaq: ANIP) announced that CEO Nikhil Lalwani will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 at 3:00 p.m. PT / 6:00 p.m. ET.
The presentation will be available via a live webcast and an archived replay on the company website under Investors > Events and Presentations. The replay will be accessible for 30 days.
ANI Pharmaceuticals (Nasdaq: ANIP) announced on December 2, 2025 the formation of the FutureVision Advisory Council to guide its ophthalmology and retina franchise within the Rare Disease business.
The council comprises seven retina and three uveitis specialists, co‑led by Arshad M. Khanani, MD (Principal Retina Advisor and Chair) and Peter Y. Chang, MD (Principal Uveitis Advisor and Chair). The council will advise on strategic advancement of current products, including ILUVIEN and Cortrophin Gel, and on development priorities to support patient care.
ANI Pharmaceuticals (Nasdaq: ANIP) announced a Board leadership change on Dec 1, 2025. Patrick D. Walsh has stepped down as Chairman and will retire from the board after completing his current term at the Company’s 2026 Annual Meeting of Stockholders. The Board unanimously elected Thomas J. Haughey, a director since May 2018, as the next Chairman. Mr. Haughey will relinquish the role of Chair of the Audit and Finance Committee and remain on that committee and the Nominating and Corporate Governance Committee.
Jeanne Thoma, a director since August 2020, will become Chair of the Audit and Finance Committee. Management framed the transition as orderly and focused on continuity while the company expands its Rare Disease business.
ANI Pharmaceuticals (Nasdaq: ANIP) announced that Chief Executive Officer Nikhil Lalwani will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 2:00 p.m. ET. The event will be available live and via archived webcast on the company website under Investors > Events and Presentations. The replay will be accessible for 90 days following the live presentation.
ANI Pharmaceuticals (Nasdaq: ANIP) announced that CEO Nikhil Lalwani will participate in a fireside chat at the Jefferies Global Healthcare Conference – London on Tuesday, November 18, 2025 at 3:00 p.m. GMT / 10:00 a.m. ET.
The live webcast and an archived replay will be available via the company’s investor website under Events and Presentations and will remain accessible for 90 days.
ANI Pharmaceuticals (Nasdaq: ANIP) reported record Q3 2025 net revenues of $227.8M, a 53.6% year‑over‑year increase, driven by Purified Cortrophin Gel $101.9M (up 93.8%). The company reported record adjusted non‑GAAP EBITDA of $59.6M and adjusted non‑GAAP diluted EPS of $2.04, with GAAP diluted EPS of $1.13.
ANI raised full‑year 2025 guidance to $854M–$873M total net revenue, adjusted non‑GAAP EBITDA of $221M–$228M, and adjusted non‑GAAP diluted EPS of $7.37–$7.64. Rare Disease is expected to represent about 50% of 2025 net revenues, including revised Cortrophin Gel guidance of $347M–$352M (≈75%–78% growth).
ANI Pharmaceuticals (Nasdaq: ANIP) will release its third quarter 2025 financial results on Friday, November 7, 2025 prior to market open.
A conference call with Nikhil Lalwani (CEO), Stephen P. Carey (CFO) and Chris Mutz (Head of Rare Disease) will be held on November 7, 2025 at 8:30 a.m. ET. Investors can join by dialing the U.S. toll-free number 800-267-6316 using conference ID 5120265 or via live webcast at www.anipharmaceuticals.com under the Investors section.
A replay will be available about two hours after the call and remain accessible for two weeks by dialing 800-839-2391 and entering access code 5120265.
ANI Pharmaceuticals (Nasdaq: ANIP) announced that results from the NEW DAY clinical trial of ILUVIEN (fluocinolone acetonide 0.19 mg) for diabetic macular edema will be presented in a late-breaking oral session at the American Academy of Ophthalmology (AAO) 2025 Retina Subspecialty Day on October 17, 2025 at 4:39 pm ET.
The release reiterates that NEW DAY results were previously reported and will be further disseminated at multiple meetings; it also restates ILUVIEN's indication for DME in patients previously treated with corticosteroids who did not have a clinically significant intraocular pressure rise, and summarizes key safety data including intraocular pressure and cataract incidence from the trials.
ANI Pharmaceuticals (NASDAQ:ANIP) has announced its participation in two upcoming investor conferences. CEO Nikhil Lalwani and the executive team will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 9:00 AM ET, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 1:50 PM ET.
Investors can access both live and archived webcasts through the company's website at www.anipharmaceuticals.com in the Investors section under Events and Presentations. The webcast replays will remain available for 90 days.
FAQ
What is the current stock price of Ani Pharmaceutic (ANIP)?
What is the market cap of Ani Pharmaceutic (ANIP)?
